Veer Bhavnagri
Net Worth

Last updated:

What is Veer Bhavnagri net worth?

The estimated net worth of Mr. Veer Bhavnagri is at least $9,347,911 as of 13 Feb 2023. He owns shares worth $618,114 as insider, has earned $5,495,397 from insider trading and has received compensation worth at least $3,234,400 in Allogene Therapeutics, Inc..

What is the salary of Veer Bhavnagri?

Mr. Veer Bhavnagri salary is $646,880 per year as Gen. Counsel & Compliance Officer in Allogene Therapeutics, Inc..

How old is Veer Bhavnagri?

Mr. Veer Bhavnagri is 42 years old, born in 1983.

What stocks does Veer Bhavnagri currently own?

As insider, Mr. Veer Bhavnagri owns shares in one company:

Company Title Shares Price per share Total value
Allogene Therapeutics, Inc. (ALLO) Gen. Counsel & Compliance Officer 577,677 $1.07 $618,114

What does Allogene Therapeutics, Inc. do?

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

ALLO logo
ALLO
Allogene Therapeutics, Inc.
$1.07

Veer Bhavnagri insider trading

Allogene Therapeutics, Inc.

Mr. Veer Bhavnagri has made 20 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of ALLO stock worth $20,550 on 13 Feb 2023.

The largest trade he's ever made was exercising 51,500 units of ALLO stock on 17 Dec 2020. As of 13 Feb 2023 he still owns at least 577,677 units of ALLO stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 3,000 $6.85 $20,550
Sale
Common Stock 3,000 $7.04 $21,120
Sale
Common Stock 5,602 $7.53 $42,189
Sale
Common Stock 8,849 $7.68 $67,960
Option
Stock Option (Right to Buy) 5,000 $2.27 $11,350
Sale
Stock Option (Right to Buy) 5,000 $2.27 $11,350
Option
Common Stock 5,000 $24.77 $123,845
Option
Stock Option (Right to Buy) 5,000 $2.27 $11,350
Sale
Common Stock 5,000 $2.27 $11,350
Option
Stock Option (Right to Buy) 5,000 $2.27 $11,350
Sale
Common Stock 5,000 $2.27 $11,350
Option
Common Stock 5,000 $2.27 $11,350
Sale
Common Stock 5,000 $2.27 $11,350
Option
Stock Option (Right to Buy) 5,000 $2.27 $11,350
Option
Common Stock 5,000 $2.27 $11,350
Option
Stock Option (Right to Buy) 5,000 $2.27 $11,350
Option
Common Stock 5,000 $2.27 $11,350
Sale
Common Stock 5,000 $2.27 $11,350
Option
Stock Option (Right to Buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Stock Option (Right to Buy) 5,000 $2.27 $11,350
Option
Common Stock 5,000 $2.27 $11,350
Sale
Common Stock 5,000 $2.27 $11,350
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 $16.01 $160,070
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 16,623 $38.03 $632,239
Option
Stock Option (Right to Buy) 10,000 $2.27 $22,700
Option
Common Stock 10,000 $2.27 $22,700
Sale
Common Stock 16,623 $25.44 $422,839
Option
Common Stock 51,500 $2.27 $116,905
Option
Stock Option (Right to Buy) 51,500 N/A N/A
Option
Stock Option (Right to Buy) 10,000 $2.27 $22,700
Sale
Common Stock 10,000 $2.27 $22,700
Option
Common Stock 10,000 $2.27 $22,700
Sale
Common Stock 25,000 $24.41 $610,275
Option
Common Stock 25,000 $2.27 $56,750
Sale
Common Stock 25,000 $36.99 $924,650
Option
Stock Option (Right to Buy) 25,000 $2.27 $56,750
Sale
Common Stock 25,000 $35.62 $890,500
Sale
Common Stock 25,000 $17.95 $448,625
Option
Common Stock 25,000 $2.27 $56,750
Option
Stock Option (Right to Buy) 25,000 $2.27 $56,750
Option
Common Stock 25,000 $2.27 $56,750
Sale
Common Stock 31,553 $36.88 $1,163,580
Option
Stock Option (Right to Buy) 25,000 $2.27 $56,750

Allogene Therapeutics key executives

Allogene Therapeutics, Inc. executives and other stock owners filed with the SEC: